ClinicalTrials.gg
RecruitingNCT07470138Updated Mar 24, 2026

Sleep Disturbance in Subjects With Autism Spectrum Disorders (ASD) in Preschool Age (18-60 Months)

An observational study in Autism Spectrum Disorder, sponsored by IRCCS Eugenio Medea. Recruiting at 2 sites in Italy. Open to participants aged 18 Months to 60 Months. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by IRCCS Eugenio Medea · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
200
Ages
18 Months to 60 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 90 studies in Autism Spectrum Disorder with a site in Italy — 48 open to participants now, 55 under way, 1 of them phase 3. Autism Spectrum Disorder · Italy.

Planned enrollment
4th of 27
200 · median 100
Started
2025
with 5 others
Observational
27 of 90
17 open now
Primary completion
2026-12
later than 43 of 54 live
Registered
84th of 90
by date
Lead sponsor
9 of 90
IRCCS Eugenio Medea

Among the 90 studies in Autism Spectrum Disorder with a site in Italy, this one is the 4th largest by planned enrollment of the 27 observational ones that give a count, is one of 6 that started in 2025, is one of 27 observational ones, reaches primary completion later than 43 of the 54 other live ones, and was the 84th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

48 of the 90 studies in Autism Spectrum Disorder with a site in Italy are open now. Recruiting first, the newest first:

42 more — sign in →

All 48 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 18 Months to 60 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Autism Spectrum Disorder with a site in Italy, or all of them as a file.
02

Study summary

An observational study is one that aims to collect data from routine clinical practice, without altering a patient's standard diagnostic and therapeutic pathway (no additional instrumental or laboratory tests beyond those performed in clinical practice are envisaged).

The overall objective of this study is to investigate sleep disorders in preschool-aged children with Autism Spectrum Disorder. Sleep plays a key role in early brain development. The prevalence of sleep disorders in childhood is reported to be between 10 and 50%, with a prevalence of up to 86% in children with neurodevelopmental disorders. Over the past few decades, numerous studies have demonstrated a significant bidirectional connection between sleep problems and various areas of child development. Therefore, early identification of sleep disorders in childhood is essential for adequate treatment and prevention of negative cognitive and socioemotional impacts.

Recent studies have demonstrated a hypothetical role for vitamin D and iron in regulating sleep. The objectives of the study are to describe sleep disturbances in a group of preschool-aged subjects with ASD (18-60 months), to measure blood ferritin and vitamin D levels, and to assess a possible correlation with specific subtypes of sleep disturbances.

Given the impact that sleep disturbances have on various areas of children's development, secondary objectives include assessing a possible positive correlation between the severity of sleep disturbances and symptoms related to Autism Spectrum Disorder and/or other psychiatric comorbidities.

03

Conditions studied

  • Autism Spectrum Disorder
04

Who can participate

Ages eligible
18 Months to 60 Months
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

subjects with ASD aged between 18 months and 60 months

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with ASD
  • aged between 18 months and 60 months

Exclusion criteria

Exclusion Criteria:

- Subjects with neurologica theraphy

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • one group

    Other: follow up

Interventions

  • Otherfollow up

    clinical evaluation as usual

06

What researchers measure

Primary outcomes

  1. Sleep Disturbance Scale for Children

    Sleep disturbances will be assessed using the Sleep Disturbance Scale for Children (SDSC) in the 3-6 year version and the 6 months-3 years version

    Time frame: once at enrolment

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2026
First posted
Mar 13, 2026
StartActual
Jan 8, 2025
Primary completionEst.
Dec 15, 2026
CompletionEst.
Dec 15, 2026
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07470138
Responsible party
Sponsor
First posted
Mar 13, 2026
Start date
Jan 8, 2025
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Mar 24, 2026

Study contacts

Elisa Mani, md
Contact
elisa.mani@lanostrafamiglia.it
031 877578 ext. +39

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion